miRNA-21 as a novel therapeutic target in lung cancer

Lung cancer is a leading cause of cancer death, and late diagnosis is one of the most important reasons for the high mortality rate. microRNAs (miRNAs) are key players in gene regulation and therefore in tumorigenesis. As far as lung carcinogenesis is concerned, miRNAs open novel fields in biomarker...

Descripción completa

Detalles Bibliográficos
Autores principales: Markou, Athina, Zavridou, Martha, Lianidou, Evi S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5310696/
https://www.ncbi.nlm.nih.gov/pubmed/28210157
http://dx.doi.org/10.2147/LCTT.S60341
_version_ 1782507908650500096
author Markou, Athina
Zavridou, Martha
Lianidou, Evi S
author_facet Markou, Athina
Zavridou, Martha
Lianidou, Evi S
author_sort Markou, Athina
collection PubMed
description Lung cancer is a leading cause of cancer death, and late diagnosis is one of the most important reasons for the high mortality rate. microRNAs (miRNAs) are key players in gene regulation and therefore in tumorigenesis. As far as lung carcinogenesis is concerned, miRNAs open novel fields in biomarker research, in diagnosis, and in therapy. In this review we focus on miR-21 in lung cancer and especially on how miR-21 is involved 1) as a biomarker in response or resistance to therapy or 2) as a therapeutic target.
format Online
Article
Text
id pubmed-5310696
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-53106962017-02-16 miRNA-21 as a novel therapeutic target in lung cancer Markou, Athina Zavridou, Martha Lianidou, Evi S Lung Cancer (Auckl) Review Lung cancer is a leading cause of cancer death, and late diagnosis is one of the most important reasons for the high mortality rate. microRNAs (miRNAs) are key players in gene regulation and therefore in tumorigenesis. As far as lung carcinogenesis is concerned, miRNAs open novel fields in biomarker research, in diagnosis, and in therapy. In this review we focus on miR-21 in lung cancer and especially on how miR-21 is involved 1) as a biomarker in response or resistance to therapy or 2) as a therapeutic target. Dove Medical Press 2016-03-02 /pmc/articles/PMC5310696/ /pubmed/28210157 http://dx.doi.org/10.2147/LCTT.S60341 Text en © 2016 Markou et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Markou, Athina
Zavridou, Martha
Lianidou, Evi S
miRNA-21 as a novel therapeutic target in lung cancer
title miRNA-21 as a novel therapeutic target in lung cancer
title_full miRNA-21 as a novel therapeutic target in lung cancer
title_fullStr miRNA-21 as a novel therapeutic target in lung cancer
title_full_unstemmed miRNA-21 as a novel therapeutic target in lung cancer
title_short miRNA-21 as a novel therapeutic target in lung cancer
title_sort mirna-21 as a novel therapeutic target in lung cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5310696/
https://www.ncbi.nlm.nih.gov/pubmed/28210157
http://dx.doi.org/10.2147/LCTT.S60341
work_keys_str_mv AT markouathina mirna21asanoveltherapeutictargetinlungcancer
AT zavridoumartha mirna21asanoveltherapeutictargetinlungcancer
AT lianidouevis mirna21asanoveltherapeutictargetinlungcancer

Ejemplares similares